Officials from USFDA visited the facilities in August last year
The US Food and Drug Administration (USFDA) has approved the sterile facility (plant-II) and solid dosage facility (plant -III) located at Verna in the adjoining coastal state, said the company release.
"The nod will facilitate generic approvals in the US market and subsequent product launches there," Indoco chairman Mr Suresh G Kare said. "It will also boost the high-margin revenue from a highly remunerative US market, the world's largest player in pharma space," he added.
Officials from USFDA visited the facilities in August last year. With this, the number of Indoco facilities having USFDA approvals have gone up to six, according to the company. These are three for finished dosages, two for APIs (active pharmaceutical ingredients) and one for analytical. The company derived 35 percent of its revenue from exports in 2013-14.